NCT03746210 Non-Invasive Characterization of Focal Liver Lesions in Liver Cirrhosis
| NCT ID | NCT03746210 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Bonn |
| Condition | Liver Cirrhoses |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2016-01-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2016-01-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to analyze non-invasive characterization focal liver lesions in patients with liver cirrhosis. The diagnostic accuracy and predictive value of non-invasive methods is studied.
Eligibility Criteria
Inclusion Criteria: * all patients with focal liver lesions and liver cirrhosis Exclusion Criteria: * no consent * under 18 years
Frequently Asked Questions
Who can join the NCT03746210 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Liver Cirrhoses. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03746210 currently recruiting?
Yes, NCT03746210 is actively recruiting participants. Visit ClinicalTrials.gov or contact University Hospital, Bonn to inquire about joining.
Where is the NCT03746210 trial being conducted?
This trial is being conducted at Bonn, Germany.
Who is sponsoring the NCT03746210 clinical trial?
NCT03746210 is sponsored by University Hospital, Bonn. The trial plans to enroll 200 participants.